PCSK9

PCSK9製品

All (7)
PCSK9阻害剤 (6)
PCSK9拮抗剤(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S7976	SBC-115076	SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.	Cancers (Basel), 2024, 16(4)713 Front Cardiovasc Med, 2021, 8:746989 Menopause, 2020, 27(10):1155-1166
A2047	Alirocumab (anti-PCSK9)	Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
S8420	R-IMPP	R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118	SBC-110736	SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116	PF-06446846 hydrochloride	PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849	PF-06446846	PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
A2043	Evolocumab (anti-PCSK9)	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
A2047	Alirocumab (anti-PCSK9)	Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
A2043	Evolocumab (anti-PCSK9)	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
S8420	R-IMPP	R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118	SBC-110736	SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116	PF-06446846 hydrochloride	PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849	PF-06446846	PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
S7976	SBC-115076	SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.	Cancers (Basel), 2024, 16(4)713 Front Cardiovasc Med, 2021, 8:746989 Menopause, 2020, 27(10):1155-1166

PCSK9阻害剤の選択性比較